Clinical Edge Journal Scan

RA: Difficult-to-treat cases persist in real world despite intensive treatment


 

Key clinical point: Considerable proportions of cases with rheumatoid arthritis (RA) are still difficult to treat in real world despite intensive treatment.

Major finding: Among patients with RA, 10.1% were categorized as having difficult-to-treat RA despite being treated intensively. Main reasons for difficulty in treating RA were multidrug resistance (34.1%), comorbidities (9.8%), and socioeconomic reasons (56.1%).

Study details: Data come from an analysis of 1,709 patients with RA who visited Keio University Hospital between 2016 and 2017.

Disclosures: The study did not receive any funding. S Takanashi reported no conflicts of interest. Y Kaneko and T Takeuchi reported receiving grants or speaker fees from various sources.

Source: Takanashi S et al. Rheumatology (Oxford). 2021 Mar 2. doi: 10.1093/rheumatology/keab209.

Recommended Reading

COVID-19 vaccination in RMD patients: Safety data “reassuring”
MDedge Rheumatology
Sustained remission more likely with biological vs. triple therapy after inadequate response to MTX
MDedge Rheumatology
Peficitinib safe and effective for long-term management of RA
MDedge Rheumatology
JAK inhibitors vs. rituximab in patients with RA and pulmonary disease
MDedge Rheumatology
Additional iguratimod may allow tapering MTX dose in RA with remission
MDedge Rheumatology
Durability of tocilizumab response in patients with RA
MDedge Rheumatology
MBDA score not sufficiently responsive to assess RA disease activity
MDedge Rheumatology
RA tied to worse long-term outcomes after myocardial infarction
MDedge Rheumatology
Habitual fish intake may prevent frailty in RA patients
MDedge Rheumatology
Low cardiorespiratory fitness contributes to excess all-cause mortality in RA
MDedge Rheumatology